175 related articles for article (PubMed ID: 15177192)
1. VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?
Lambrechts D; Storkebaum E; Carmeliet P
Trends Mol Med; 2004 Jun; 10(6):275-82. PubMed ID: 15177192
[TBL] [Abstract][Full Text] [Related]
2. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death.
Lambrechts D; Storkebaum E; Morimoto M; Del-Favero J; Desmet F; Marklund SL; Wyns S; Thijs V; Andersson J; van Marion I; Al-Chalabi A; Bornes S; Musson R; Hansen V; Beckman L; Adolfsson R; Pall HS; Prats H; Vermeire S; Rutgeerts P; Katayama S; Awata T; Leigh N; Lang-Lazdunski L; Dewerchin M; Shaw C; Moons L; Vlietinck R; Morrison KE; Robberecht W; Van Broeckhoven C; Collen D; Andersen PM; Carmeliet P
Nat Genet; 2003 Aug; 34(4):383-94. PubMed ID: 12847526
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor in amyotrophic lateral sclerosis and other neurodegenerative diseases.
Bogaert E; Van Damme P; Van Den Bosch L; Robberecht W
Muscle Nerve; 2006 Oct; 34(4):391-405. PubMed ID: 16856151
[TBL] [Abstract][Full Text] [Related]
4. Does VEGF represent a potential treatment for amyotrophic lateral sclerosis?
Iłzecka J
Curr Opin Investig Drugs; 2006 Jan; 7(1):54-9. PubMed ID: 16425672
[TBL] [Abstract][Full Text] [Related]
5. A new piece of the ALS puzzle.
Cleveland JL
Nat Genet; 2003 Aug; 34(4):357-8. PubMed ID: 12923539
[No Abstract] [Full Text] [Related]
6. Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype.
Lambrechts D; Poesen K; Fernández-Santiago R; Al-Chalabi A; Del Bo R; Van Vught PW; Khan S; Marklund SL; Brockington A; van Marion I; Anneser J; Shaw C; Ludolph AC; Leigh NP; Comi GP; Gasser T; Shaw PJ; Morrison KE; Andersen PM; Van den Berg LH; Thijs V; Siddique T; Robberecht W; Carmeliet P
J Med Genet; 2009 Dec; 46(12):840-6. PubMed ID: 18413368
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor attenuates neurodegenerative changes in the NSC-34 motor neuron cell line induced by cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients.
Kulshreshtha D; Vijayalakshmi K; Alladi PA; Sathyaprabha TN; Nalini A; Raju TR
Neurodegener Dis; 2011; 8(5):322-30. PubMed ID: 21389676
[TBL] [Abstract][Full Text] [Related]
8. Another angiogenic gene linked to amyotrophic lateral sclerosis.
Lambrechts D; Lafuste P; Carmeliet P; Conway EM
Trends Mol Med; 2006 Aug; 12(8):345-7. PubMed ID: 16843725
[TBL] [Abstract][Full Text] [Related]
9. The role of AMPA receptors and VEGF in ALS.
Van Damme P
Verh K Acad Geneeskd Belg; 2009; 71(4):241-50. PubMed ID: 20084835
[TBL] [Abstract][Full Text] [Related]
10. VEGF and ALS.
Sathasivam S
Neurosci Res; 2008 Oct; 62(2):71-7. PubMed ID: 18656504
[TBL] [Abstract][Full Text] [Related]
11. Lack of association between VEGF polymorphisms and ALS in a Dutch population.
Van Vught PW; Sutedja NA; Veldink JH; Koeleman BP; Groeneveld GJ; Wijmenga C; Uitdehaag BM; de Jong JM; Baas F; Wokke JH; Van den Berg LH
Neurology; 2005 Nov; 65(10):1643-5. PubMed ID: 16301496
[TBL] [Abstract][Full Text] [Related]
12. Amyotrophic lateral sclerosis (ALS): a phylogenetic disease of the corticomotoneuron?
Eisen A; Kim S; Pant B
Muscle Nerve; 1992 Feb; 15(2):219-24. PubMed ID: 1549143
[TBL] [Abstract][Full Text] [Related]
13. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice.
Zheng C; Sköld MK; Li J; Nennesmo I; Fadeel B; Henter JI
Biochem Biophys Res Commun; 2007 Nov; 363(4):989-93. PubMed ID: 17923114
[TBL] [Abstract][Full Text] [Related]
14. Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons.
Subramanian V; Crabtree B; Acharya KR
Hum Mol Genet; 2008 Jan; 17(1):130-49. PubMed ID: 17916583
[TBL] [Abstract][Full Text] [Related]
15. Neural stem cells LewisX+ CXCR4+ modify disease progression in an amyotrophic lateral sclerosis model.
Corti S; Locatelli F; Papadimitriou D; Del Bo R; Nizzardo M; Nardini M; Donadoni C; Salani S; Fortunato F; Strazzer S; Bresolin N; Comi GP
Brain; 2007 May; 130(Pt 5):1289-305. PubMed ID: 17439986
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor protects spinal cord motoneurons against glutamate-induced excitotoxicity via phosphatidylinositol 3-kinase.
Tolosa L; Mir M; Asensio VJ; Olmos G; Lladó J
J Neurochem; 2008 May; 105(4):1080-90. PubMed ID: 18182045
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid vascular endothelial growth factor in patients with amyotrophic lateral sclerosis.
Iłzecka J
Clin Neurol Neurosurg; 2004 Sep; 106(4):289-93. PubMed ID: 15297002
[TBL] [Abstract][Full Text] [Related]
18. Examining the interaction of apo E and neurotoxicity on a murine model of ALS-PDC.
Wilson JM; Petrik MS; Moghadasian MH; Shaw CA
Can J Physiol Pharmacol; 2005 Feb; 83(2):131-41. PubMed ID: 15791286
[TBL] [Abstract][Full Text] [Related]
19. VEGF promoter haplotype and amyotrophic lateral sclerosis (ALS).
Terry PD; Kamel F; Umbach DM; Lehman TA; Hu H; Sandler DP; Taylor JA
J Neurogenet; 2004; 18(2):429-34. PubMed ID: 15763997
[TBL] [Abstract][Full Text] [Related]
20. Cytoskeletal defects in amyotrophic lateral sclerosis (motor neuron disease).
Julien JP; Millecamps S; Kriz J
Novartis Found Symp; 2005; 264():183-92; discussion 192-6, 227-30. PubMed ID: 15773754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
